S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:ADAG

Adagene (ADAG) Stock Price, News & Analysis

$2.64
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
$2.51
$2.64
50-Day Range
$2.50
$3.58
52-Week Range
$1.10
$4.38
Volume
5,364 shs
Average Volume
12,355 shs
Market Capitalization
$116.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Adagene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
89.4% Upside
$5.00 Price Target
Short Interest
Healthy
0.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.90) to ($1.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.39 out of 5 stars

Medical Sector

479th out of 907 stocks

Pharmaceutical Preparations Industry

215th out of 424 stocks

ADAG stock logo

About Adagene Stock (NASDAQ:ADAG)

Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

ADAG Stock Price History

ADAG Stock News Headlines

Adagene Inc. (NASDAQ:ADAG) Short Interest Down 38.6% in March
“More countries ditch the US dollar”
Since March 2018, China started purchasing oil in gold-backed yuan. By December 2022, Foreign Minister Wang Yi stated that Chinese-Arab relations experienced a "historic improvement." after arab nations ditched the dollar to trade with China. On June 6, 2023 China told its banks to slash interest rates on US dollars.
“More countries ditch the US dollar”
Since March 2018, China started purchasing oil in gold-backed yuan. By December 2022, Foreign Minister Wang Yi stated that Chinese-Arab relations experienced a "historic improvement." after arab nations ditched the dollar to trade with China. On June 6, 2023 China told its banks to slash interest rates on US dollars.
How Is The Market Feeling About Adagene?
Morgan Stanley 'encouraged' by 2 cPRs reported by Adagene
Adagene price target lowered by 40c at Morgan Stanley, here's why
Are Medical Stocks Lagging Medpace (MEDP) This Year?
See More Headlines
Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADAG
Fax
N/A
Employees
174
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+89.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$18.11 million
Book Value
$1.61 per share

Miscellaneous

Free Float
34,764,000
Market Cap
$116.48 million
Optionable
Not Optionable
Beta
0.44
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Peter P. Luo Ph.D. (Age 58)
    Co- Founder, Chairman, CEO and President of R&D
  • Mr. Man Kin Tam M.B.A. (Age 47)
    CFO & Director
  • Dr. Jc Xu M.D. (Age 59)
    Ph.D., Chief Scientific Officer
  • Ms. Ami Celeste Knoefler
    Vice President of Investor Relations & Corporate Communications
  • Ms. Ling Zhou
    Head of Human Resources
  • Dr. Qinghai Zhao (Age 63)
    Chief Manufacturing Officer
  • Ms. Yan Li M.B.A. (Age 49)
    Senior VP of Bioinformatics & Information Technology and Director
  • Ms. Xiaohong She (Age 57)
    Senior VP & Head of Clinical Operations
  • Dr. Guizhong Liu Ph.D. (Age 53)
    Senior Vice President of Early Drug Discovery
  • Mr. Alexander Goergen (Age 37)
    VP & Head of Business Development

ADAG Stock Analysis - Frequently Asked Questions

Should I buy or sell Adagene stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADAG shares.
View ADAG analyst ratings
or view top-rated stocks.

What is Adagene's stock price target for 2024?

1 analysts have issued 12-month target prices for Adagene's stock. Their ADAG share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 89.4% from the stock's current price.
View analysts price targets for ADAG
or view top-rated stocks among Wall Street analysts.

How have ADAG shares performed in 2024?

Adagene's stock was trading at $1.9314 at the beginning of the year. Since then, ADAG shares have increased by 36.7% and is now trading at $2.64.
View the best growth stocks for 2024 here
.

Are investors shorting Adagene?

Adagene saw a decline in short interest in March. As of March 31st, there was short interest totaling 13,700 shares, a decline of 38.6% from the March 15th total of 22,300 shares. Based on an average trading volume of 105,400 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.
View Adagene's Short Interest
.

When did Adagene IPO?

Adagene (ADAG) raised $133 million in an initial public offering (IPO) on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager.

How do I buy shares of Adagene?

Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADAG) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners